Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric or Gastroesophageal Junction Adenocarcinoma”

494 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 494 results

Testing effectiveness (Phase 2)Study completedNCT03686488
What this trial is testing

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 23
Testing effectiveness (Phase 2)UnknownNCT04367025
What this trial is testing

Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer

Who this might be right for
Gastric Cancer
Chinese PLA General Hospital 70
Testing effectiveness (Phase 2)UnknownNCT05019794
What this trial is testing

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaSolid Tumor
LianBio LLC 80
Testing effectiveness (Phase 2)Study completedNCT02443883
What this trial is testing

Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company 164
Early research (Phase 1)Not Yet RecruitingNCT06748872
What this trial is testing

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Who this might be right for
Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)+2 more
Medigene AG 55
Not applicableUnknownNCT03045770
What this trial is testing

MFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Who this might be right for
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
Fujian Cancer Hospital 150
Large-scale testing (Phase 3)Study completedNCT05008783
What this trial is testing

AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 610
Testing effectiveness (Phase 2)Study completedNCT01630083
What this trial is testing

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

Who this might be right for
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of EsophagusCLDN18.2-positive Gastric Adenocarcinoma
Astellas Pharma Global Development, Inc. 252
Early research (Phase 1)Study completedNCT02013154
What this trial is testing

DKN-01 in Combination With Paclitaxel or Pembrolizumab

Who this might be right for
Esophageal NeoplasmsAdenocarcinoma of the Gastroesophageal JunctionGastroesophageal Cancer+2 more
Leap Therapeutics, Inc. 151
Not applicableNot Yet RecruitingNCT07552402
What this trial is testing

Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

Who this might be right for
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Harbin Medical University 150
Testing effectiveness (Phase 2)Study completedNCT00515411
What this trial is testing

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastroesophageal Junction AdenocarcinomaGastric Cancer
Memorial Sloan Kettering Cancer Center 111
Large-scale testing (Phase 3)Study completedNCT01170663
What this trial is testing

Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

Who this might be right for
Gastric Cancer
Eli Lilly and Company 665
Large-scale testing (Phase 3)Not Yet RecruitingNCT07068516
What this trial is testing

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

Who this might be right for
Gastric Cancer Stage
Xiangdong Cheng 470
Testing effectiveness (Phase 2)Looking for participantsNCT05640609
What this trial is testing

Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Who this might be right for
Stomach Neoplasm
West China Hospital 57
Testing effectiveness (Phase 2)Looking for participantsNCT06776770
What this trial is testing

A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer

Who this might be right for
Gastric Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center 52
Testing effectiveness (Phase 2)UnknownNCT04098796
What this trial is testing

PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction AdenocarcinomaAFP
China Medical University, China 30
Large-scale testing (Phase 3)Study completedNCT02578368
What this trial is testing

Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Who this might be right for
Gastric Cancer
Krankenhaus Nordwest 183
Large-scale testing (Phase 3)Active Not RecruitingNCT04208347
What this trial is testing

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Who this might be right for
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital 580
Large-scale testing (Phase 3)Study completedNCT03042611
What this trial is testing

Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

Who this might be right for
Gastric CancerGastric Adenocarcinoma
Elevar Therapeutics 460
Not applicableLooking for participantsNCT05993234
What this trial is testing

Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Who this might be right for
HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 257
Load More Results